Gálffy Gabriella, Emmeluth Melanie, Koltun Arkady, Kopietz Ferdinand, Nguyen Duc Tung, Kuhl Hans Christian
Onco-Pulmonology Department, Pest County Pulmonology Hospital, Törökbálint, Hungary.
Global Medical Affairs, MEDA Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany.
J Asthma Allergy. 2021 Apr 7;14:335-345. doi: 10.2147/JAA.S291747. eCollection 2021.
Allergic rhinitis (AR) is characterized by nasal and ocular symptoms, and substantially impacts the quality of life. Therapy selection for patients with AR depends on several factors, including symptom severity, age, patient preference, patient adherence, and cost.
The purpose of this multicenter, noninterventional, cross-sectional survey was to evaluate current therapy decisions in routine clinical practice for patients with symptomatic AR, and to determine how these decisions are linked to experiences with previous treatments and current symptom severity as assessed by aVAS. The survey included patients aged 18 years or older in Spain and 12 years or older in Hungary who consulted a physician for treatment of AR symptoms. Physicians recorded AR symptom burden in the previous 7 days, previous AR treatments, and the current AR therapy decision made at the visit.
Overall, 72.9% of 181 patients (Spain) and 67.1% of 228 patients (Hungary) had received treatment in the previous 7 days. Among patients who had received step 3 treatment, 82.9% (Spain) and 75.8% (Hungary) received a free combination of intranasal corticosteroid (INCS) and antihistamines. Despite the high number of pretreated patients in both countries, 72.9% and 78.9% in Spain and Hungary, respectively, reported uncontrolled symptoms (VAS ≥50 mm). Of pretreated patients, 58.3% (Spain) and 61.4% (Hungary) received a step-up in treatment during the visit. Physicians more often prescribed a fixed combination of INCS and intranasal antihistamine than a free combination. However, of patients with uncontrolled symptoms who received previous therapy, 28.0% (Hungary) and 40.6% (Spain) did not receive a step-up as suggested by the guidelines.
Many patients suffering from acute AR symptoms consulted with their physician because of insufficient medications. Not all patients with uncontrolled symptoms received a step-up in treatment, underscoring the need for improved physician education to enhance AR management and control in accordance with consensus treatment guidelines.
变应性鼻炎(AR)以鼻和眼部症状为特征,对生活质量有重大影响。AR患者的治疗选择取决于多个因素,包括症状严重程度、年龄、患者偏好、患者依从性和费用。
这项多中心、非干预性横断面调查的目的是评估有症状AR患者在常规临床实践中的当前治疗决策,并确定这些决策如何与既往治疗经历以及通过视觉模拟量表(aVAS)评估的当前症状严重程度相关联。该调查纳入了西班牙18岁及以上、匈牙利12岁及以上因AR症状就诊的患者。医生记录了患者前7天的AR症状负担、既往AR治疗情况以及此次就诊时做出的当前AR治疗决策。
总体而言,181例西班牙患者中有72.9%以及228例匈牙利患者中有67.1%在过去7天内接受了治疗。在接受第3步治疗的患者中,82.9%(西班牙)和75.8%(匈牙利)接受了鼻用糖皮质激素(INCS)和抗组胺药的联合治疗。尽管两国接受过治疗的患者数量众多,但西班牙和匈牙利分别有72.9%和78.9%的患者报告症状未得到控制(VAS≥50 mm)。在接受过治疗的患者中,58.3%(西班牙)和61.4%(匈牙利)在此次就诊时接受了升级治疗。医生更常开具INCS和鼻用抗组胺药的固定组合而非联合治疗。然而,在既往接受过治疗但症状未得到控制的患者中,28.0%(匈牙利)和40.6%(西班牙)未按照指南建议接受升级治疗。
许多患有急性AR症状的患者因药物不足而咨询医生。并非所有症状未得到控制的患者都接受了升级治疗,这突出表明需要加强医生教育,以根据共识治疗指南改善AR的管理和控制。